Minneapolis, Minnesota-based Bio-Techne Corporation (TECH) develops, manufactures, and sells life science reagents, ...

Bio-Techne develops specialized reagents and diagnostic solutions for global research and clinical markets in the life sciences sector.

Techne Corporation, the Minneapolis-based biotechnology company that now does business under the “Bio-Techne” brand, recently announced that it’s investing $10 million CyVek, Inc.—and it might ...

Bio-Techne (TECH) is back in focus after institutional investors such as Jefferies Financial Group and Madison Investments increased their exposure, alongside earnings that topped expectations and ...

Shares of Bio-Techne Corp. TECH rallied 1.82% to $54.87 Monday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 0.83% to 6,795.99 and ...

Bio-Techne Corp. topped $1 billion in full-year sales for the first time, its latest results showed Thursday, and the Minneapolis-based life science firm said it is beginning a two-year leadership ...

Techne Corporation—whose longtime CEO resigned in November and protested the search process for his successor—said Monday that it has appointed a new chief executive. Techne, a Minneapolis-based maker ...

Madison Investments, an investment advisor, released its fourth-quarter 2025 investor letter for “Madison Mid Cap Fund”. A copy of the letter can be downloaded here. The Russell Midcap Index ended an ...

The collaboration between Leica Biosystems and Bio-Techne expands access to advanced RNA ISH technology for clinical laboratories across the United States ...

Bio-Techne Corp. is expanding into the realm of diagnostics with its ExoDx Prostate cancer test and a development pipeline of comparable products — a new area of business for the company, best known ...

RBC Capital on Tuesday upgraded Bio-Techne Corporation (NASDAQ:TECH), noting that recent end-market weakness has over-penalized one of the best assets in the life science and tools (LST) sector, ...